Note some dates / timeframe
$Lisata Therapeutics (LSTA.US)$Has some anticipated clinical milestones set for the next 18 months. Multiple clinical studies are advancing, with the Phase 2b ASCEND study in metastatic pancreatic ductal adenocarcinoma having completed enrollment for one of its cohorts, with results expected by the fourth quarter of 2024. The BOLSTER and CENDIFOX trials are progressing as planned, and the study of certepetide in glioblastoma multiforme has started dosing. These developments suggest that Lisata Therapeutics is on a clear path to potential future approvals and the design of a subsequent Phase 3 trial![]()
免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。
更多信息
評論
登錄發表評論
